Bilcare Global Clinical Supplies (GCS), a provider of clinical trial materials, services and project management that last month opened new global headquarters in San Francisco, has bolstered its Phase III capabilities by upgrading a large-scale bottling line at its US facility in Phoenixville, Pennsylvania and taking on new blistering technology for expanded packaging capacity in America and Europe.

“By investing in large-scale equipment technology, we’re offering our customers what no other partner can: a true, integrated partnership that can take them from beginning-phase research and development through Phase III,” said Vito Mangiardi, chief executive officer of Bilcare GCS.

According to the company, whose Pune, India-based parent Bilcare offers research, clinical and packaging services to the pharmaceutical industry, the investments in the Kalish bottling line and Pentapack blistering system are part of its commitment to providing customers with comprehensive services spanning the entire clinical supply chain. Industry “has tired of working with multiple partners during different clinical trial phases”, Mangiardi commented.

The Pentapack CT1200L system will enable Bilcare GCS to undertake high-volume packaging runs for large-scale clinical trials and stability tests. It also gives the company extra flexibility in trial design and execution to meet individual client needs.

During its 2007-2008 fiscal year, Bilcare GCS nearly doubled its global workforce, including significant additions to its executive team, completed a US$2.3 million capital investment programme in the US and expanded its Indian facility in Rajgurunagar, near Pune, the company noted.

It also made a US$21 million commitment to a new clinical supplies facility in South Wales that will replace an existing facility acquired with Powys-based DHP Ltd in 2006.